Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Boston Convention and Exhibition Center

Jun 23, 2013 8:30 AM - Jun 27, 2013 12:45 PM

415 Summer Street, , Boston, MA 02210 , USA

DIA 2013 49th Annual Meeting: Advancing Therapeutic Innovation and Regulatory Science

Hot Topics in Statistics: Working Together Effectively to Transform Our Science

Session Chair(s)

Steve  Wilson, PhD

Steve Wilson, PhD

Senior Staff Fellow, OB, OTS, CDER

FDA, United States

On February 24, 2010, FDA launched its Advancing Regulatory Science Initiative to transform the way medical products are developed, evaluated, and manufactured. This Regulatory Science is defined as “the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of all FDA-regulated products.” This science needs to be a team effort, requiring integrated/applied thought and effort from all of the players – the professionals associated with the discovery, development and review of new drugs, biologics and devices. Statisticians need to know and think about this new science, constantly defining and applying rigorous quantitative thinking in making the decisions to discover, move forward and regulate new products. It’s bigger than all of us in industry, government and academia, and it needs to be collaborative and strategic. This forum will describe the challenges and opportunities associated with making this happen.

Learning Objective : Discuss key developments associated with the regulatory science initiatives and how they relate to statistics; Recognize the impact of the new guidance, collaborative efforts and the role of statistics in the quantitative thinking needed to transform how medical products are developed, evaluated and manufactured; Identify opportunities for FDA, industry and academia to collaborate in developing methodologies for the quantitative decision-making needed for medical product development.

Speaker(s)

Robert T. O'Neill, PhD

FDA Perspective

Robert T. O'Neill, PhD

FDA, United States

Senior Statistical Advisor, Office of Translational Sciences, CDER

Ralph B. D'Agostino, PhD, MA

Advisory Committee Perspective

Ralph B. D'Agostino, PhD, MA

Boston University, United States

Chair, Mathematics and Statistics Department

Marcia  Testa, MPH

Academic Perspective

Marcia Testa, MPH

Harvard School of Public Health, United States

Senior Lecturer

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.